Question 1

Am I eligible to participate in this trial based on my previous treatments?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Open Label Continuation Study in Moderate to Severe Psoriasis clinical trial (NCT00626002). Contact the study team or your healthcare provider for specific answers.

Question 2

What are the potential side effects of continuing ABT-874 for a longer period?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Open Label Continuation Study in Moderate to Severe Psoriasis clinical trial (NCT00626002). Contact the study team or your healthcare provider for specific answers.

Question 3

How does this treatment compare to other options available for my psoriasis?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Open Label Continuation Study in Moderate to Severe Psoriasis clinical trial (NCT00626002). Contact the study team or your healthcare provider for specific answers.

Question 4

What kind of monitoring will be involved during the study?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Open Label Continuation Study in Moderate to Severe Psoriasis clinical trial (NCT00626002). Contact the study team or your healthcare provider for specific answers.

Question 5

How will this trial impact my current treatment plan?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Open Label Continuation Study in Moderate to Severe Psoriasis clinical trial (NCT00626002). Contact the study team or your healthcare provider for specific answers.

Question 6

What should I expect during the visits and how often will they occur?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Open Label Continuation Study in Moderate to Severe Psoriasis clinical trial (NCT00626002). Contact the study team or your healthcare provider for specific answers.

What this study is about